ANI PHARMACEUTICALS, INC. (NASDAQ:ANIP) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.
|
Submission of Matters to a Vote of Security Holders. |
On May 17, 2017, ANI Pharmaceuticals, Inc. (the Company) held its
2017 Annual Meeting of Stockholders. The following matters, all
of which were set forth in the Company’s proxy statement for the
2017 Annual Meeting (Annual Meeting), were voted on and approved
by the Company’s stockholders. The voting results for each
proposal are set forth below.
1. The individuals listed below were elected at the Annual
Meeting to serve as directors of the Company until the next
annual meeting of shareholders and until their successors are
duly elected and qualified:
| Nominee | For | Against | Abstained | BrokerNon-Votes | ||||
| 1. Robert E. Brown, Jr. | 6,992,097 | 555,987 | 6,604 | 2,576,661 | ||||
| 2. Arthur S. Przybyl | 7,134,281 | 417,434 | 2,973 | 2,576,661 | ||||
| 3. Fred Holubow | 7,347,502 | 204,136 | 3,050 | 2,576,661 | ||||
| 4. Tracy L. Marshbanks, Ph.D. | 7,347,994 | 203,674 | 3,020 | 2,576,661 | ||||
| 5. Thomas A. Penn | 6,756,615 | 791,462 | 6,611 | 2,576,661 | ||||
| 6. Daniel Raynor | 6,886,364 | 665,501 | 2,823 | 2,576,661 |
2. The Companys Fifth Amended and Restated 2008 Stock Incentive
Plan was approved.
| For | Against | Abstained | Broker Non-Votes | |||
| 7,340,037 | 204,903 | 9,748 | 2,576,661 |
3. The appointment of EisnerAmper LLP as the Company’s
independent registered public accounting firm for the year ending
December 31, 2017 2017, as described in the proxy materials, was
approved.
| For | Against | Abstained | Broker Non-Votes | |||
| 10,041,849 | 73,095 | 16,405 |
4. The executive compensation of the Company’s named executive
officers, as described in the proxy materials, was approved.
| For | Against | Abstained | Broker Non-Votes | |||
| 6,575,271 | 965,622 | 13,795 | 2,576,661 |
About ANI PHARMACEUTICALS, INC. (NASDAQ:ANIP)
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations. Its generic products include Esterified Estrogen with Methyltestosterone, Etodolac, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup, Nimodipine, Opium Tincture, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Lithobid, Reglan and Vancocin. It has over two pharmaceutical manufacturing facilities located in Baudette, Minnesota that are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products. Its two facilities have a combined manufacturing, packaging and laboratory capacity totaling approximately 173,000 square feet. ANI PHARMACEUTICALS, INC. (NASDAQ:ANIP) Recent Trading Information
ANI PHARMACEUTICALS, INC. (NASDAQ:ANIP) closed its last trading session 00.00 at 47.89 with 126,184 shares trading hands.
